Home  |  Contact
Due to scheduled maintenance work, this service will not be available from Tuesday August 23rd 06:00 pm until Wednesday August 24th 08:00 am CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot P43080: Variant p.Leu151Phe

Guanylyl cyclase-activating protein 1
Gene: GUCA1A
Variant information

Variant position:  151
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Leucine (L) to Phenylalanine (F) at position 151 (L151F, p.Leu151Phe).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (L) to large size and aromatic (F)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In COD3 and CORD14.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  151
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  201
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.





Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 2 – 201 Guanylyl cyclase-activating protein 1
Domain 131 – 166 EF-hand 4
Binding site 144 – 144
Binding site 146 – 146
Binding site 148 – 148
Binding site 150 – 150
Binding site 155 – 155

Literature citations

A novel GCAP1 missense mutation (L151F) in a large family with autosomal dominant cone-rod dystrophy (adCORD).
Sokal I.; Dupps W.J.; Grassi M.A.; Brown J. Jr.; Affatigato L.M.; Roychowdhury N.; Yang L.; Filipek S.; Palczewski K.; Stone E.M.; Baehr W.;
Invest. Ophthalmol. Vis. Sci. 46:1124-1132(2005)
Cited for: VARIANT CORD14 PHE-151;

Autosomal dominant cone dystrophy caused by a novel mutation in the GCAP1 gene (GUCA1A).
Jiang L.; Katz B.J.; Yang Z.; Zhao Y.; Faulkner N.; Hu J.; Baird J.; Baehr W.; Creel D.J.; Zhang K.;
Mol. Vis. 11:143-151(2005)
Cited for: VARIANT COD3 PHE-151;

Mutations in the GUCA1A gene involved in hereditary cone dystrophies impair calcium-mediated regulation of guanylate cyclase.
Kitiratschky V.B.D.; Behnen P.; Kellner U.; Heckenlively J.R.; Zrenner E.; Jaegle H.; Kohl S.; Wissinger B.; Koch K.-W.;
Hum. Mutat. 30:E782-E796(2009)

Characterization of GUCA1A-associated dominant cone/cone-rod dystrophy: low prevalence among Japanese patients with inherited retinal dystrophies.
Mizobuchi K.; Hayashi T.; Katagiri S.; Yoshitake K.; Fujinami K.; Yang L.; Kuniyoshi K.; Shinoda K.; Machida S.; Kondo M.; Ueno S.; Terasaki H.; Matsuura T.; Tsunoda K.; Iwata T.; Nakano T.;
Sci. Rep. 9:16851-16851(2019)
Cited for: VARIANTS COD3 ILE-42; GLU-68; ILE-80; ASN-99; SER-99; PHE-151 AND ARG-184;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.